Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

PD-L1 promoter methylation mediates the resistance response to anti-PD-1 therapy in NSCLC patients with EGFR-TKI resistance

27 Sept 2017

Abstract excerpt

// Yan Zhang 1 , Cheng Xiang 1 , Yuling Wang 2 , Yuanyuan Duan 1 , Ci Liu 1 and Yajing Zhang 1 1 Department of Oncology, The First Hospital of Shijiazhuang City, Shijiazhuang, Hebei 050010, China 2 Clinical Research Center, Shijiazhuang Fifth Hospital, Shijiazhuang, Hebei 050021, China Correspondence to: Cheng Xiang, email: chengxiangsjz@163.com Keywords: PD-L1 promoter methylation; non-small cell lung cancer;...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Chronic Myeloid Leukemia Treatments
Share to Gastrointestinal Tumor Research and Treatment
Share to Lung Cancer Treatments and Mutations

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 29254184
DOI: 10.18632/oncotarget.21328

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

PD-L1 promoter methylation mediates the resistance response to anti-PD-1 therapy in NSCLC patients with EGFR-TKI resistancePMID 29254184Read ↗

PD-L1 methylation restricts PD-L1/PD-1 interactions to control cancer immune surveillanceSemantic proximity Read ↗

The new idea of cancer immunotherapy: the expression of PD-L1 may reveal the immunological mechanism of resistance of EGFR-TKIsSemantic proximity Read ↗

PD-L1 confers resistance to EGFR mutation-independent tyrosine kinase inhibitors in non-small cell lung cancer via upregulation of YAP1 expressionSemantic proximity Read ↗

[Research Progress of Anti-PD-1/PD-L1 Therapy for Non-small Cell Lung Cancer with EGFR Mutation].Semantic proximity Read ↗

Abnormal genome-wide DNA methylation induced by cisplatin may contribute to the chemo-resistance of human small cell lung cancerSemantic proximity Read ↗

[A Real-world Study on the Expression Characteristics of PD-L1 in Patients with Advanced EGFR Positive NSCLC and Its Relationship with the Therapeutic Efficacy of EGFR-TKIs].Semantic proximity Read ↗

PiRNA-Hsap_1847317 may serve as a novel biomarker of PD-1 inhibitor resistance in patients with advanced non-small cell lung cancerSemantic proximity Read ↗

Understanding and Targeting the Epigenetic Regulation to Overcome EGFR-TKIs Resistance in Human Cancer.Semantic proximity Read ↗

PD-1/PD-L1 pathway in non-small-cell lung cancer and its relation with EGFR mutation.Semantic proximity Read ↗

The progress and confusion of anti-PD1/PD-L1 immunotherapy for patients with advanced non-small cell lung cancer.Semantic proximity Read ↗

Immunotherapy-based combination strategies for treatment of EGFR-TKI-resistant non-small-cell lung cancer.Semantic proximity Read ↗

Study on Targeted Drugs for Non-Small Cell NSCLC with PD-1PD-L1 Signaling Pathway.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.